DGIdb - NIMODIPINE Drug Record

NIMODIPINE chembl:CHEMBL1428 Approved

Alternate Names:

NYMALIZE
NIMOTOP
NIMODIPINE
BAY-E-9736
ISOPROPYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
NIMODIPINUM
2,6-DIMETHYL-4-(3'-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-BETA-METHOXYETHYL ESTER 5-ISOPROPYL ESTER
NIMODIPINO
2,6-DIMETHYL-4-(3'-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-Β-METHOXYETHYL ESTER 5-ISOPROPYL ESTER
BAY E 9736
ISOPROPYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
NIMOTOP®
chemidplus:66085-59-4
rxcui:7426
drugbank:00393
pubchem.compound:4497
chembl:CHEMBL1428

Drug Info:

Drug Categories	selective calcium channel blockers with mainly vascular effects
Drug Categories	nicotinic acids
Drug Categories	dihydropyridines
FDA Approval	1988
Drug Class	small molecule
Drug Indications	Vasodilator Agents
Drug Indications	Antihypertensive Agents
Year of Approval	1988
Drug Class	vasodilator agents
Drug Class	antihypertensive agents
Drug Groups	investigational
Drug Categories	agents causing hyperkalemia
Drug Categories	antiarrhythmic agents
Drug Categories	bradycardia-causing agents
Drug Categories	calcium-regulating hormones and agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	moderate risk qtc-prolonging agents
Drug Categories	p-glycoprotein inhibitors
Drug Categories	qtc prolonging agents
Drug Categories	vasodilating agents

(6 More Sources)

Publications:

Kumar et al., 2010, L-type calcium channel blockers, morphine and pain: Newer insights., Indian J Anaesth
Keyrouz et al., 2007, Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage., Crit Care
Weant et al., 2010, Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage., Pharmacotherapy
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Kim et al., 2009, Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage., J Korean Neurosurg Soc
Peterson et al., 2006, Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore., Mol. Pharmacol.
Dong et al., 2010, Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking., Invest. Ophthalmol. Vis. Sci.
Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol
Marchetti et al., 1996, High affinity block by nimodipine of the internal calcium elevation in chronically depolarized rat cerebellar granule neurons., Neurosci. Lett.
Guntinas-Lichius et al., 1997, Nimodipine maintains in vivo the increase in GFAP and enhances the astroglial ensheathment of surviving motoneurons in the rat following permanent target deprivation., J. Neurocytol.
Koh et al., 1995, Potentiated necrosis of cultured cortical neurons by neurotrophins., Science
Hu et al., 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro., Mol. Pharmacol.
Dietz et al., 2008, A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity., Hypertension
Roos et al., 2001, Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage., Stroke
Gahm et al., 2005, Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine., Acta Neurochir (Wien)
Sinnegger-Brauns et al., 2009, Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms., Mol. Pharmacol.
Liu et al., Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats., Eur J Drug Metab Pharmacokinet
Yu DD et al., 2013, Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery., Bioorg Med Chem
Ko et al., 1993, Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells., J. Hypertens.

NIMODIPINE CACNB4

Interaction Score: 1.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20661350 17705883 20335610 20334460 19844625

Sources:
DrugBank
NIMODIPINE CACNB3

Interaction Score: 1.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20661350 17705883 20335610 20334460 19844625

Sources:
DrugBank
NIMODIPINE CACNB1

Interaction Score: 1.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20661350 17705883 20335610 20334460 19844625

Sources:
DrugBank
NIMODIPINE CACNB2

Interaction Score: 0.85

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20661350 17705883 20334460 11752352 19844625

Sources:
DrugBank
NIMODIPINE CACNA1F

Interaction Score: 0.68

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

Specific Action of the Ligand Antagonist

PMIDs:
20661350 20335610 20334460 19844625

Sources:
DrugBank GuideToPharmacology ChemblInteractions
NIMODIPINE CACNA1D

Interaction Score: 0.64

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

Direct Interaction yes

PMIDs:
20661350 17705883 19029287 20335610 20334460 19844625

Sources:
DrugBank ChemblInteractions
NIMODIPINE CACNA1S

Interaction Score: 0.61

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

Direct Interaction yes

Direct Interaction? False

PMIDs:
20661350 17705883 16675661 20335610 20334460 19844625

Sources:
DrugBank GuideToPharmacology ChemblInteractions
NIMODIPINE CACNA1C

Interaction Score: 0.51

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

PMIDs:
20661350 17705883 20335610 20334460 11752352 19205682 19844625 8731425

Sources:
PharmGKB DrugBank ChemblInteractions
NIMODIPINE FOS

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8301097

Sources:
NCI

NIMODIPINE NR3C2

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Details of Interaction inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain

Endogenous Drug? False

PMIDs:
18250364

Sources:
DrugBank GuideToPharmacology ChemblInteractions

NIMODIPINE NTF3

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7725105

Sources:
NCI
NIMODIPINE CACNG1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
None found

Sources:
TEND TdgClinicalTrial
NIMODIPINE GFAP

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9192289

Sources:
NCI
NIMODIPINE SERPINE1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11486117

Sources:
NCI
NIMODIPINE NOS2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16044358

Sources:
NCI
NIMODIPINE CFTR

Interaction Score: 0.09

Interaction Types & Directionality:

activator (activating)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Potentiation

PMIDs:
None found

Sources:
GuideToPharmacology
NIMODIPINE NR1H4

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23688559

Sources:
DTC
NIMODIPINE AHR

Interaction Score: 0.07

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
17327465

Sources:
DrugBank
NIMODIPINE CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19205682

Sources:
PharmGKB
NIMODIPINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14743973

Sources:
NCI
NIMODIPINE ATAD5

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00393

Version: 5.1.7

Alternate Names:

NIMODIPINE DrugBank Drug Name

66085-59-4 CAS Number

Nimodipine Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Kumar et al., 2010, L-type calcium channel blockers, morphine and pain: Newer insights., Indian J Anaesth

Dong et al., 2010, Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking., Invest. Ophthalmol. Vis. Sci.

Weant et al., 2010, Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage., Pharmacotherapy

TEND: NIMODIPINE
- Version: 01-August-2011
Alternate Names:

NIMODIPINE Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Drug Class vasodilator agents

Year of Approval 1988

Publications:
TdgClinicalTrial: NIMODIPINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antihypertensive Agents

Drug Indications Vasodilator Agents

Drug Class small molecule

Publications:
DTC: NIMODIPINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1428 ChEMBL Drug ID

Drug Info:

Publications:

Yu DD et al., 2013, Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery., Bioorg Med Chem

NCI: NIMODIPINE

Version: 14-September-2017

Alternate Names:

C692 NCI drug code

Drug Info:

Publications:

Koh et al., 1995, Potentiated necrosis of cultured cortical neurons by neurotrophins., Science

Roos et al., 2001, Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage., Stroke

Ko et al., 1993, Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells., J. Hypertens.

PharmGKB: nimodipine
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol
GuideToPharmacology: 53801057
- Version: 29-September-2020
Alternate Names:

NIMODIPINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Nimodipine
- Version: 2020.06.01
Alternate Names:

D0XN1F TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1428
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1428
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Voltage-gated L-type calcium channel blocker
Specific Action of the Ligand	Antagonist

Specific Action of the Ligand	Antagonist
Details of Interaction	inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain
Endogenous Drug?	False

NIMODIPINE	DrugBank Drug Name
66085-59-4	CAS Number
Nimodipine	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

NIMODIPINE Drug Record

NIMODIPINE chembl:CHEMBL1428 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20661350 17705883 20335610 20334460 19844625

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20661350 17705883 20335610 20334460 19844625

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20661350 17705883 20335610 20334460 19844625

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20661350 17705883 20334460 11752352 19844625

Sources: DrugBank

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Voltage-gated L-type calcium channel blocker Specific Action of the Ligand Antagonist

PMIDs: 20661350 20335610 20334460 19844625

Sources: DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Voltage-gated L-type calcium channel blocker Direct Interaction yes

PMIDs: 20661350 17705883 19029287 20335610 20334460 19844625

Sources: DrugBank ChemblInteractions

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Voltage-gated L-type calcium channel blocker Direct Interaction yes Direct Interaction? False

PMIDs: 20661350 17705883 16675661 20335610 20334460 19844625

Sources: DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Voltage-gated L-type calcium channel blocker

PMIDs: 20661350 17705883 20335610 20334460 11752352 19205682 19844625 8731425

Sources: PharmGKB DrugBank ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8301097

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Antagonist Details of Interaction inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain Endogenous Drug? False

PMIDs: 18250364

Sources: DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7725105

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: None found

Sources: TEND TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9192289

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11486117

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16044358

Sources: NCI

Interaction Types & Directionality: activator (activating)

Interaction Info: Endogenous Drug? False Specific Action of the Ligand Potentiation

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23688559

Sources: DTC

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 17327465

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19205682

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20661350 17705883 20335610 20334460 19844625

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20661350 17705883 20335610 20334460 19844625

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20661350 17705883 20335610 20334460 19844625

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20661350 17705883 20334460 11752352 19844625

Sources:
DrugBank

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

Specific Action of the Ligand Antagonist

PMIDs:
20661350 20335610 20334460 19844625

Sources:
DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

Direct Interaction yes

PMIDs:
20661350 17705883 19029287 20335610 20334460 19844625

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

Direct Interaction yes

Direct Interaction? False

PMIDs:
20661350 17705883 16675661 20335610 20334460 19844625

Sources:
DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Voltage-gated L-type calcium channel blocker

PMIDs:
20661350 17705883 20335610 20334460 11752352 19205682 19844625 8731425

Sources:
PharmGKB DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
8301097

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Details of Interaction inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain

Endogenous Drug? False

PMIDs:
18250364

Sources:
DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
7725105

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
None found

Sources:
TEND TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
9192289

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11486117

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16044358

Sources:
NCI

Interaction Types & Directionality:

activator (activating)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Potentiation

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
23688559

Sources:
DTC

Interaction Types & Directionality:

agonist (activating)

PMIDs:
17327465

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
19205682

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
14743973

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

NIMODIPINE DrugBank Drug Name

66085-59-4 CAS Number

Nimodipine Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

NIMODIPINE Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Drug Class vasodilator agents

Year of Approval 1988

Drug Info:

Drug Indications Antihypertensive Agents

Drug Indications Vasodilator Agents

Drug Class small molecule

Alternate Names:

CHEMBL1428 ChEMBL Drug ID

Publications:

Yu DD et al., 2013, Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery., Bioorg Med Chem

Alternate Names:

C692 NCI drug code

Publications:

Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol

Alternate Names:

NIMODIPINE GuideToPharmacology Ligand Name